By PPN News Staff
The KidCOVE study showed a robust neutralizing antibody response among children 6 to 11 years of age who received two doses of the Moderna messenger RNA (mRNA) COVID-19 vaccine.
Moderna plans to submit these data to the FDA for an expanded emergency use authorization.
KidCOVE (ClinicalTrials.gov Identifier: NCT04796896) is a randomized, observer-blinded, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity and effectiveness of two 50-mcg doses